Progesterone for Prevention of Premature Birth
Progesterone for Prevention of Premature Birth
May 16, 2011 (Issue: 1364)
The FDA recently approved the marketing of
hydroxyprogesterone caproate injection (Makena –
Ther-Rx) for prevention of preterm birth in women
with a singleton pregnancy who have a history of singleton
spontaneous preterm birth.
1. T Zakar and S Mesiano. How does progesterone relax the uterus in pregnancy? N Engl J Med 2011; 364:972.
2. PJ Meis et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348:2379.
3. P Majhi et al. Intravaginal use of natural micronised progesterone to prevent pre-term birth: a randomized trial in India. J Obstet Gynaecol 2009; 29:493.
4. JM O’ Brien et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007; 30:687.
5. EA DeFranco et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007; 30:697.
6. EB Fonseca et al. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007; 357:462.
7. SS Hassan et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011; April 6 (epub).
8. DJ Rouse et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007; 357:454.
9. JE Norman et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomized, double-blind, placebo-controlled study and meta-analysis. Lancet 2009; 373:2034.
10. Food and Drug Administration. FDA Statement on Makena. Available at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm249025.htm. Accessed May 9, 2011.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Progesterone for Prevention of Premature Birth
Article code: 1364b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
